We are a diversified healthcare company with core businesses consisting of our Crinone® (progesterone gel) (“Crinone”) franchise and our fee-for-service pharmaceutical development and manufacturing business called Juniper Pharma Services (“JPS”). In addition, we are seeking to use our differentiated intravaginal ring (“IVR”) technology to advance a pipeline of product candidates intended to address unmet needs in women’s health, through either internal development or external partnering. We are actively exploring business development collaborations including opportunities that could leverage our IVR technology and/or the pharmaceutical development capabilities of JPS. In January 2018, we announced that we would be exploring strategic alternatives in order to enhance shareholder value. We engaged Rothschild Global Advisory Group as our independent financial advisor to assist us and our Board of Directors in evaluating potential strategic alternatives.
Company profile
Ticker
JNP
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Columbia Laboratories Inc
SEC CIK
Corporate docs
IRS number
592758596
Latest filings (excl ownership)
15-12B
Securities registration termination
31 Aug 18
CT ORDER
Confidential treatment order
30 Aug 18
EFFECT
Notice of effectiveness
30 Aug 18
EFFECT
Notice of effectiveness
30 Aug 18
EFFECT
Notice of effectiveness
30 Aug 18
EFFECT
Notice of effectiveness
30 Aug 18
EFFECT
Notice of effectiveness
30 Aug 18
EFFECT
Notice of effectiveness
30 Aug 18
EFFECT
Notice of effectiveness
30 Aug 18
EFFECT
Notice of effectiveness
30 Aug 18
Latest ownership filings
Institutional ownership, Q4 2020
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
IFP Advisors | 0.00 | $0.00 |